Adjuvant treatment in high-risk breast cancer

被引:0
|
作者
Mansi, JL
机构
来源
BRITISH JOURNAL OF HOSPITAL MEDICINE | 1996年 / 56卷 / 2-3期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
下载
收藏
页码:112 / 112
页数:1
相关论文
共 50 条
  • [21] Adjuvant Therapy in High-Risk Prostate Cancer
    Shevach, Jeffrey
    Chaudhuri, Parul
    Morgans, Alicia K.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 45 - 53
  • [22] Immediate breast reconstruction in the high-risk adjuvant setting
    Wey, PD
    Highstein, JB
    Borah, GL
    ANNALS OF PLASTIC SURGERY, 1997, 38 (04) : 342 - 344
  • [23] Adjuvant therapy in high-risk colon cancer
    Bleiberg, H
    SEMINARS IN ONCOLOGY, 2000, 27 (05) : 48 - 59
  • [24] From adjuvant to neoadjuvant chemotherapy for high-risk breast
    Bonadonna, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 43 - 43
  • [25] Adjuvant chemotherapy for high-risk endometrial cancer
    Pustilnik, T
    Burke, TW
    SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (01) : 23 - 28
  • [26] Adjuvant chemoradiotherapy for high-risk pancreatic cancer
    Wang, M. L. C.
    Foo, K. F.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (01) : 43 - 48
  • [27] New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer
    Minot-This, Marie-Sophie
    Deleuze, Antoine
    BULLETIN DU CANCER, 2022, 109 (10) : 988 - 989
  • [28] Optimal duration of adjuvant bisphosphonate treatment for high-risk early breast cancer: Results from a SUCCESS trial
    Lu, Mingbei
    Ren, Beibei
    Rao, Lingyan
    THORACIC CANCER, 2022, 13 (03) : 519 - 520
  • [29] Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer
    Semiglazov, VF
    Bozhok, AA
    Ivanova, OA
    Iranov, VG
    Golubeva, OM
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S41 - S41
  • [30] Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer
    Semiglazov, VF
    Bozhok, AA
    Moiseyenko, VM
    Ivanova, OA
    Ivanov, VG
    Golubeva, OM
    ANNALS OF ONCOLOGY, 1998, 9 : 5 - 5